Abzena to build US biologics manufacturing plant in North Carolina
New facility will be research partnering company’s sixth global site and will be dedicated to mammalian biologics
Global research partnering organisation Abzena has announced it will build its new biologics manufacturing site in Sanford, North Carolina, generating around 325 jobs in the area.
The company announced it was adding a sixth global site in January. The new plant – which will cost over $200 million and will be equipped with 12 X 2000L bioreactors -- will be dedicated to cGMP manufacturing capacity for mammalian biologics.
Abzena said the design of the facility has been optimized for phase III and commercial manufacturing of biologics.
As a result of the project’s phased approach to construction, four modular suites will initially come online, each including up to two 2000L bioreactors before two further 2000L suites are added.
Additionally, the site will be equipped to handle existing and new advances in manufacturing such as continuous manufacturing and perfusion. Manufacturing is expected to start in mid-2022.
“We are pleased to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer,” said Jonathan Goldman, CEO of Abzena in a statement.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...